Back to results
US 2022/0010313 A1Published application
Crispr/cas-related methods and compositions for treating herpes simplex virus
AssigneeEditas Medicine, Inc.
InventorsAri E. Friedland, Penrose O'Donnell, David A. Bumcrot
Life of this patent
Estimating the term…
Abstract
CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
Claims23
-27. (canceled)
A vector comprising a polynucleotide encoding a gRNA molecule comprising a targeting domain that is complementary with a target sequence of a HSV viral gene selected from the group consisting of a RS1 gene, a RL2 gene, and a LAT gene.
-33. (canceled)
Dependencies are inferred from the claim text.